Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients

Nephron - Clinical Practice

Volumn 100, Issue 4, 2005, Pages

  Sjøland, Jonas Angel ^a,b   Pedersen, Robert Smith ^a   Jespersen, Jørgen ^a   Gram, Jørgen ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b ESBJERG HOSPITAL   (Denmark)

Author keywords

C reactive protein; Chronic inflammation; Fibrinogen; Heparin; Interleukin 6; Intraperitoneal administration; Peritoneal dialysis

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HEPARIN; INTERLEUKIN 6; ISOTONIC SOLUTION; SODIUM CHLORIDE; TINZAPARIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; DOUBLE BLIND PROCEDURE; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULTRAFILTRATION;

ADULT; AGED; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 21344463080     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085289     Document Type: Article

References (20)

1. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000;35:S117-S131.
2. Zoccali C: Cardiovascular risk in uraemic patients - Is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15:454-457.
3. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimburger O, Lindholm B: Chronic inflammation in peritoneal dialysis: The search for the holy grail? Perit Dial Int 2004;24:327-339.
4. Libby P: Inflammation in atherosclerosis. Nature 2002;420:868-874.
5. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P: C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: The PRIME Study. Arterioscler Thromb Vasc Biol 2003;23:1255-1261.
6. Danesh J, Wheeler JG, Hirschneid GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
7. Trocme SD, Li H: Effect of heparin-surface-modified intraocular lenses on postoperative inflammation after phacoemulsification: A randomized trial in a United States patient population. Heparin-Surface-Modified Lens Study Group. Ophthalmology 2000;107:1031-1037.
8. Lose G, Jespersen J, Frandsen B, Hojensgard JC, Astrap T: Subcutaneous heparin in the treatment of interstitial cystitis. Scand J Urol Nephrol 1985;19:27-29.
9. Jespersen J, Astrup T: Chronic interstitial cystitis and subcutaneous heparin. Lancet 1985;ii:1010-1011.
10. Sjøland JA, Pedersen RS, Jespersen J, Gram J: Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004;19:1264-1268.
11. Sifil A, Mermut C, Yenicerioglu Y, Cavdar C, Gumustekin M, Celik A, Yuksel F, Camsari T: Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003;19:28-30.
12. Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991, pp 467-471.
13. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P: Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003;18:1042-1045.
14. Prisco D, Paniccia R, Bandinelli B, Gori AM, Attanasio M, Giusti B, Comeglio M, Abbate R, Gensini GF, Serneri GG: Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Int J Clin Lab Res 1998;28:170-173.
15. Myrup B, Jensen T, Gram J, Kluft C, Jespersen J, Deckert T: No effect of unfractioned or low molecular weight heparin treatment on markers of vascular wall and hemostatic function in incipient diabetic nephropathy. Diabetes Care 1997;20:1615-1619.
16. Oldgren J, Wallentin L, Grip L, Linder R, Norgaard BL, Siegbahn A: Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease. Eur Heart J 2003;24:86-93.
17. Jilma-Stohlawetz P, Folman CC, dem Borne AE, Pernerstorfer T, Hollenstein U, Knechtelsdorfer M, Eichler HG, Jilma B: Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med 2001;137:64-69.
18. Furman KI, Gomperts ED, Hockley J: Activity of intraperitoneal heparin during peritoneal dialysis. Clin Nephrol 1978;9:15-18.
19. Gries E, Paar D, Graben N, Bock KD: Intraperitoneal heparin in peritoneal dialysis and its effect on fibrinopeptide A in plasma and dialysate. Haemostasis 1989;19:21-25.
20. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L: Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998;160:5130-5135.